Akebia Signs a License Agreement with Medice Arzneimittel Pütter GmbH&Co.KG to Commercialize Vafseo for Anemia Associated with CKD
Shots:
- Akebia will receive $10M up front, ~$100M in commercial milestones for rights to Vafseo in the EU & Australia along with royalty up to 30% of net sales. Medice has the rights to market & sells Vafseo in the EEA, UK, Switzerland & Australia
- Akebia gets the right to develop Vafseo for anemia due to CKD in non-dialysis patients & also retains the rights in other indications. Medice will commercialize Vafseo for both indications in the defined territory if Akebia exercises those rights where Akebia also retains 70% of the net profit margin of any sales of the licensed product
- If Akebia decides to develop vadadustat in other indications & looks for a collaboration partner in the territory, Medice has the right of first refusal for an expanded collaboration
Ref: PR Newswire | Image: Akebia
Related News:- Akebia Receives the MHRA’s Approval of Vafseo for Symptomatic Anemia Associated with Chronic Kidney Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
